Plus deals involving Menarini/VenatoRx, Orion/Glykos, Roche/MOMA, Janssen/Elektrofi, Galapagos/BridGene along with 13 other transactions.

China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.

With the first half of 2022 ending, two Chinese developers of innovative drugs - antibody specialist Chongqing Genrix Biopharmaceutical and Suzhou Teligene, which focuses on small molecules, are looking to go public on Shanghai’s STAR Market, ending a recent drought of biopharma listings.

AstraZeneca takes second license of antisense candidate under 2012 pact with Ionis, this time for kidney disease. Aldeyra is working with J&J on novel immune-modulating drugs for systemic inflammatory conditions.